# SPR720 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/spr720

> SPR720, sponsored by Spero Therapeutics, Inc. (SPRO): 1 recorded catalyst.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | SPR720 |
| Codes | SPR720 |
| Sponsor | Spero Therapeutics, Inc. (SPRO) https://sec-api.dev/companies/spro/catalysts |
| Indications | ntm-pd not meeting its primary endpoint |
| Modality |  |
| FDA designations | fast track, orphan |

## Timeline

### October 29, 2024: interim data readout

- Status: completed, met. Date confidence: exact. Stage: 2. Indication: NTM-PD not meeting its primary endpoint.
- First seen 2024-11-14, last confirmed 2025-08-12.
- SEC Form 10-Q (accession 0000950170-25-107388): "On October 29, 2024, we announced that we suspended development activities for our SPR720 oral program based on an interim analysis of the Phase 2a proof-of-concept study of SPR720 for the treatment of NTM-PD not meeting its primary endpoint." https://www.sec.gov/Archives/edgar/data/1701108/000095017025107388/spro-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-107388): "For example, on October 29, 2024, we announced that we suspended development activities for our SPR720 oral program based on an interim analysis of the Phase 2a proof-of-concept study of SPR720 for the treatment of NTM-PD not meeting its primary endpoint." https://www.sec.gov/Archives/edgar/data/1701108/000095017025107388/spro-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-070380): "On October 29, 2024, we announced that we suspended development activities for our SPR720 oral program based on an interim analysis of the Phase 2a proof-of-concept study of SPR720 for the treatment of NTM-PD not meeting its primary endpoint." https://www.sec.gov/Archives/edgar/data/1701108/000095017025070380/spro-20250331.htm
- SEC Form 10-K (accession 0000950170-25-046125): "On October 29, 2024, we announced that we suspended development activities for our SPR720 oral program based on an interim analysis of the Phase 2a proof-of-concept study of SPR720 for the treatment of NTM-PD not meeting its primary endpoint." https://www.sec.gov/Archives/edgar/data/1701108/000095017025046125/spro-20241231.htm
- SEC Form 10-Q (accession 0000950170-24-127016): "On October 29, 2024, the Company announced that it would suspend its current development activities for SPR720 based on an interim analysis of the Phase 2a proof-of-concept study of SPR720 for the treatment of NTM-PD not meeting its primary endpoint." https://www.sec.gov/Archives/edgar/data/1701108/000095017024127016/spro-20240930.htm
- SEC Form 10-Q (accession 0000950170-24-127016): "On October 29, 2024, we announced that we would suspend current development activities for SPR720 based on an interim analysis of the Phase 2a proof-of-concept study of SPR720 for the treatment of NTM-PD not meeting its primary endpoint." https://www.sec.gov/Archives/edgar/data/1701108/000095017024127016/spro-20240930.htm
- SEC Form 10-Q (accession 0000950170-24-127016): "On October 29, 2024, we announced that we would suspend development activities for SPR720 based on based on an interim analysis of the Phase 2a proof-of-concept study of SPR720 for the treatment of NTM-PD not meeting its primary endpoint." https://www.sec.gov/Archives/edgar/data/1701108/000095017024127016/spro-20240930.htm
- SEC Form 10-Q (accession 0000950170-25-107388): "Subsequently, in October 2024, we announced that we would suspend current development activities for SPR720 based on an interim analysis of the Phase 2a proof-of-concept study of SPR720 for the treatment of NTM-PD not meeting its primary endpoint." https://www.sec.gov/Archives/edgar/data/1701108/000095017025107388/spro-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-070380): "Subsequently, in October 2024, we announced that we would suspend current development activities for SPR720 based on an interim analysis of the Phase 2a proof-of-concept study of SPR720 for the treatment of NTM-PD not meeting its primary endpoint." https://www.sec.gov/Archives/edgar/data/1701108/000095017025070380/spro-20250331.htm
- SEC Form 10-K (accession 0000950170-25-046125): "Subsequently, in October 2024, we announced that we would suspend current development activities for SPR720 based on an interim analysis of the Phase 2a proof-of-concept study of SPR720 for the treatment of NTM-PD not meeting its primary endpoint." https://www.sec.gov/Archives/edgar/data/1701108/000095017025046125/spro-20241231.htm
- SEC Form 10-Q (accession 0000950170-24-127016): "Subsequently, in October 2024, we announced that we would suspend current development activities for SPR720 based on an interim analysis of the Phase 2a proof-of-concept study of SPR720 for the treatment of NTM-PD not meeting its primary endpoint." https://www.sec.gov/Archives/edgar/data/1701108/000095017024127016/spro-20240930.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/spr720.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "SPR720 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/spr720

```bibtex
@misc{secapidev_pdufa_spr720_20261116,
  title        = {SPR720 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/spr720}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_spr720_20261116","title":"SPR720 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/spr720","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
